March 2024 Quarterly Activities Report & Appendix 4C
Released
Released
Announcement PDF
ASX Announcement
30 April 2024
Avecho Quarterly Activities Report and Appendix 4C
Melbourne, Australia, 30 April 2024: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the
“Company”) is pleased to release its Quarterly Activities Report and Appendix 4C for the quarter ended
31 March 2024.
During the quarter, the Company marked a major milestone, with the commencement of its pivotal
Phase III trial of its proprietary CBD soft gel capsule targeting insomnia. Further details on the structure
of the study are outlined below.
PHASE III STUDY COMMENCES FOLLOWING FINAL ETHICS APPROVAL
In March 2024, the Company commenced patient recruitment for its Phase III clinical trial testing its
oral cannabidiol TPM®-enhanced soft-gel capsule for insomnia, the largest insomnia study of its kind
testing cannabidiol.
The trial is seeking to recruit 519 patients across sites located in Melbourne, Sydney, Central Coast,
Brisbane, and Perth. The treatment groups will compare nightly cannabidiol doses of 75 and 150mg
cannabidiol with placebo over an 8-week dosing period.
The trial has been designed to meet the requirements of key global regulatory agencies, including
Australia’s key regulatory body, the Therapeutics Goods Administration (“TGA”). The Company met
with the TGA during the quarter to present the final Phase III insomnia clinical trial design and planned
submission strategy. The TGA has not recommended any changes to the trial design and submission
strategy and the program has commenced as planned. Although non-binding and given without
prejudice the positive response from the TGA reinforces Avecho’s confidence that the trial, if successful,
may support an Australian regulatory approval.
Australia's unique regulatory environment provides an outstanding commercial opportunity to Avecho.
During 2020, the TGA announced it would allow cannabidiol products to be sold over the counter in
Australia subject to appropriate regulatory approvals, therefore incentivising pharmaceutical
development and a shift away from unregistered cannabinoid products. To date, no Phase III
cannabidiol trials in Australia have succeeded. Avecho is targeting to be the first company to gain such
approval with its oral CBD TPM soft-gel capsule for the treatment of insomnia.
Avecho’s trial will recruit eligible participants who are 18 years or older; who have had difficulty getting
to sleep, staying asleep and/or waking up earlier in the morning than desired, for at least the past three
months (or are diagnosed with insomnia); and/or have a regular time period spent in bed, either
sleeping or trying to sleep.
The commencement of the trial follow Avecho receiving final ethics approval after it submitted
amendments to the study in December 2023.
The ethics approval included measures to streamline and enhance efficiency within the trial, reinforcing
the planned study design, further separating the methodology away from that employed in unsuccessful
Phase III trials for CBD in the treatment of insomnia in Australia to date. It also allows Avecho to more
efficiently deploy funds made available to the Company following its capital raising in 2023.
Avecho Biotechnology Limited | ASX:AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
The commencement of the study produced wide ranging media interest with segments broadcast
nationally on Channel 9 (https://www.youtube.com/watch?v=s6GCPzJ92Rc), Channel 7
(https://twitter.com/7NewsMelbourne/status/1773228526193492070) and a variety of radio networks.
The Company will update the market as recruitment continues.
CORPORATE
During the quarter ended 31 March 2024, the Company invested ~A$406K in R&D activities and
incurred employment, administration and corporate costs of ~A$376K. At the end of the quarter, the
Company held ~A$4.6 million in cash.
Payments to related parties and their associates during the quarter, as outlined in Section 6 of the
accompanying Appendix 4C to these quarterly activities report, were ~A$53K.
For enquiries, please contact
Dr Paul Gavin
Chief Executive Officer
Avecho Biotechnology Limited
+61 3 9002 5000
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health
products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®).
TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to
enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.
Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market and is also developing TPM® to enhance the feed efficiency and health of
livestock.
See more here - avecho.com.au
Forward-Looking Statements
Certain statements in this announcement are forward looking statements. Forward looking statements
can generally be identified by the use of words such as “anticipate”, “estimate”, “expect”, “project”,
“intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forwardlooking statements speak only as at the date of this announcement. These statements are based on
current expectations and beliefs and, by their nature, are subject to a number of known and unknown
risks and uncertainties that could cause the actual results, performances and achievements to differ
materially from any expected future results, performance or achievements expressed or implied by such
forward looking statements.
No representation, warranty or assurance (express or implied) is given or made by AVE that the
forward-looking statements contained in this announcement are accurate, complete, reliable or
adequate or that they will be achieved or prove to be correct. Except for any statutory liability which
cannot be excluded, AVE and its respective officers, employees and advisers expressly disclaim any
responsibility for the accuracy or completeness of the forward-looking statements and exclude all
liability whatsoever (including negligence) for any direct or indirect loss or damage which may be
suffered by any person as a consequence of any information in this announcement or any error or
omission therefrom.
2
Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, AVE
disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking
statements in these materials to reflect any change in expectations in relation to any forward-looking
statements or any change in events, conditions or circumstances on which any statement is based.
Nothing in these materials shall under any circumstances create an implication that there has been no
change in the affairs of AVE since the date of the announcement.
3
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
AVECHO BIOTECHNOLOGY LIMITED
ABN
Quarter ended (“current quarter”)
32 056 482 403
31 March 2024
Consolidated statement of cash flows
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Current quarter
$A’000
Year to date (3
months)
$A’000
1
1
(a) research and development
(406)
(406)
(b) product manufacturing and operating
costs
(70)
(70)
(c) advertising and marketing
-
-
(d) leased assets
-
-
(e) staff costs*
(140)
(140)
(f) administration and corporate costs
(g) patent portfolio costs
(236)
(40)
(236)
(40)
-
-
1.3
Dividends received (see note 3)
1.4
Interest received
14
14
1.5
Interest and other costs of finance paid
(2)
(2)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
-
1.8
Other (EMDG)
-
-
1.9
Net cash from / (used in) operating
activities
(879)
(879)
*A percentage of staff costs are reallocated to payments for research and development.
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(h) entities
-
-
(i)
businesses
-
-
(j)
property, plant and equipment
-
-
(k) investments
-
-
(l)
-
-
intellectual property
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
(m) other non-current assets
2.2
Current quarter
$A’000
Year to date (3
months)
$A’000
-
-
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
-
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
-
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9(a)
Other – Payment of principal element of
lease liabilities
(19)
(19)
3.9(b)
Others
-
-
3.10
Net cash from / (used in) financing
activities
(19)
(19)
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
5,504
5,504
(879)
(879)
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (3
months)
$A’000
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
-
-
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
(19)
(19)
4.5
Effect of movement in exchange rates on
cash held
1
1
4.6
Cash and cash equivalents at end of
period
4,607
4,607
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
4,591
5,488
5.2
Call deposits
16
16
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
4,607
5,504
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
(53)
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
-
N/A
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(879)
8.2
Cash and cash equivalents at quarter end (item 4.6)
4,607
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
4,607
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
5.24
-
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
30 April 2024
Authorised by: By the Board of Avecho Biotechnology Limited
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover